Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.54 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.53 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.53 |
| ▸ | ROCK2 | O75116 | 11/20 | 0.52 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24131487 | 1.00 | MAOB (0.54) | MAOBIMPDH2IMPDH1ROCK2RPS6KB1 | |
| SCHEMBL26530525 | 0.93 | MAOB (0.52) | MAOBIMPDH2IMPDH1ROCK2RPS6KB1 | |
| SCHEMBL26528011 | 0.91 | ROCK2 (0.53) | MAOBIMPDH2IMPDH1ROCK2RPS6KB1 | |
| SCHEMBL30292035 | 0.88 | ROCK2 (0.58) | MAOBIMPDH2IMPDH1ROCK2RPS6KB1 | |
| SCHEMBL22158349 | 0.88 | ROCK2 (0.58) | MAOBIMPDH2IMPDH1ROCK2RPS6KB1 | |
| SCHEMBL22165399 | 0.86 | MAOB (0.68) | MAOBIMPDH2IMPDH1ROCK2RPS6KB1 | |
| SCHEMBL30292044 | 0.86 | MAOB (0.68) | MAOBIMPDH2IMPDH1ROCK2RPS6KB1 | |
| SCHEMBL22158319 | 0.86 | MAOB (0.68) | MAOBIMPDH2IMPDH1ROCK2RPS6KB1 | |
| SCHEMBL30292017 | 0.86 | MAOB (0.68) | MAOBIMPDH2IMPDH1ROCK2RPS6KB1 | |
| SCHEMBL30292055 | 0.86 | MAOB (0.68) | MAOBIMPDH2IMPDH1ROCK2RPS6KB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630542-B2 | Compounds and their use as therapeutically active substances in the treatment and/or prevention of diseases involving the retinal pigment epithelium | ENDOGENA THERAPEUTICS, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20230322749-A1 | NEW COMPOUNDS AND THEIR USE AS THERAPEUTICALLY ACTIVE SUBSTANCES IN THE TREATMENT AND/OR PREVENTION OF DISEASES INVOLVING THE RETINAL PIGMENT EPITHELIUM | ENDOGENA THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| EP-4167999-A1 | NEW COMPOUNDS AND THEIR USE AS THERAPEUTICALLY ACTIVE SUBSTANCES IN THE TREATMENT AND/OR PREVENTION OF DISEASES INVOLVING THE RETINAL PIGMENT EPITHELIUM | Endogena Therapeutics, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| CN-115916192-A | Novel compounds and their use as therapeutically active substances for the treatment and/or prophylaxis of diseases in which the retinal pigment epithelium is involved | 内生疗法公司 | 2023-04-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322749-A1 | NEW COMPOUNDS AND THEIR USE AS THERAPEUTICALLY ACTIVE SUBSTANCES IN THE TREATMENT AND/OR PREVENTION OF DISEASES INVOLVING THE RETINAL PIGMENT EPITHELIUM | ALDH1A2, NR2E3, RB1 | MAOB 972/4885IMPDH2 4176/4885IMPDH1 4302/4885 |
| US-12630542-B2 | Compounds and their use as therapeutically active substances in the treatment and/or prevention of diseases involving the retinal pigment epithelium | ALDH1A2, NR2E3, GFRA1 | MAOB 1171/4885IMPDH2 3741/4885IMPDH1 3736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.